107 related articles for article (PubMed ID: 23067318)
1. An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
Angst D; Janser P; Quancard J; Buehlmayer P; Berst F; Oberer L; Beerli C; Streiff M; Pally C; Hersperger R; Bruns C; Bassilana F; Bollbuck B
J Med Chem; 2012 Nov; 55(22):9722-34. PubMed ID: 23067318
[TBL] [Abstract][Full Text] [Related]
2. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Pan S; Mi Y; Pally C; Beerli C; Chen A; Guerini D; Hinterding K; Nuesslein-Hildesheim B; Tuntland T; Lefebvre S; Liu Y; Gao W; Chu A; Brinkmann V; Bruns C; Streiff M; Cannet C; Cooke N; Gray N
Chem Biol; 2006 Nov; 13(11):1227-34. PubMed ID: 17114004
[TBL] [Abstract][Full Text] [Related]
3. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.
Piali L; Froidevaux S; Hess P; Nayler O; Bolli MH; Schlosser E; Kohl C; Steiner B; Clozel M
J Pharmacol Exp Ther; 2011 May; 337(2):547-56. PubMed ID: 21345969
[TBL] [Abstract][Full Text] [Related]
4. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
Quancard J; Bollbuck B; Janser P; Angst D; Berst F; Buehlmayer P; Streiff M; Beerli C; Brinkmann V; Guerini D; Smith PA; Seabrook TJ; Traebert M; Seuwen K; Hersperger R; Bruns C; Bassilana F; Bigaud M
Chem Biol; 2012 Sep; 19(9):1142-51. PubMed ID: 22999882
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
Trifilieff A; Fozard JR
J Pharmacol Exp Ther; 2012 Aug; 342(2):399-406. PubMed ID: 22570366
[TBL] [Abstract][Full Text] [Related]
6. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.
Weckbecker G; Pally C; Beerli C; Burkhart C; Wieczorek G; Metzler B; Morris RE; Wagner J; Bruns C
Transpl Int; 2010 May; 23(5):543-52. PubMed ID: 20003043
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
Murakami A; Takasugi H; Ohnuma S; Koide Y; Sakurai A; Takeda S; Hasegawa T; Sasamori J; Konno T; Hayashi K; Watanabe Y; Mori K; Sato Y; Takahashi A; Mochizuki N; Takakura N
Mol Pharmacol; 2010 Apr; 77(4):704-13. PubMed ID: 20097776
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).
Ren F; Deng G; Wang H; Luan L; Meng Q; Xu Q; Xu H; Xu X; Zhang H; Zhao B; Li C; Guo TB; Yang J; Zhang W; Zhao Y; Jia Q; Lu H; Xiang JN; Elliott JD; Lin X
J Med Chem; 2012 May; 55(9):4286-96. PubMed ID: 22500954
[TBL] [Abstract][Full Text] [Related]
9. Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists.
Hennessy EJ; Grewal G; Byth K; Kamhi VM; Li D; Lyne P; Oza V; Ronco L; Rooney MT; Saeh JC; Su Q
Bioorg Med Chem Lett; 2015; 25(10):2041-5. PubMed ID: 25890801
[TBL] [Abstract][Full Text] [Related]
10. Discovery of S1P agonists with a dihydronaphthalene scaffold.
Kurata H; Kusumi K; Otsuki K; Suzuki R; Kurono M; Takada Y; Shioya H; Komiya T; Mizuno H; Ono T; Hagiya H; Minami M; Nakade S; Habashita H
Bioorg Med Chem Lett; 2011 Jul; 21(13):3885-9. PubMed ID: 21641216
[TBL] [Abstract][Full Text] [Related]
11. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
Hale JJ; Lynch CL; Neway W; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Parent SA; Chrebet G; Bergstrom J; Card D; Ferrer M; Hodder P; Strulovici B; Rosen H; Mandala S
J Med Chem; 2004 Dec; 47(27):6662-5. PubMed ID: 15615513
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells.
Nodai A; Machida T; Izumi S; Hamaya Y; Kohno T; Igarashi Y; Iizuka K; Minami M; Hirafuji M
Life Sci; 2007 Apr; 80(19):1768-76. PubMed ID: 17382352
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
14. S1P receptor mediated activity of FTY720 phosphate mimics.
Högenauer K; Hinterding K; Nussbaumer P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1485-7. PubMed ID: 20153186
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.
Nakamura T; Asano M; Sekiguchi Y; Mizuno Y; Tamaki K; Nara F; Kawase Y; Yabe Y; Nakai D; Kamiyama E; Urasaki-Kaneno Y; Shimozato T; Doi-Komuro H; Kagari T; Tomisato W; Inoue R; Nagasaki M; Yuita H; Oguchi-Oshima K; Kaneko R; Nishi T
Eur J Med Chem; 2012 May; 51():92-8. PubMed ID: 22405291
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists.
Ibrahim MA; Johnson HW; Jeong JW; Lewis GL; Shi X; Noguchi RT; Williams M; Leahy JW; Nuss JM; Woolfrey J; Banica M; Bentzien F; Chou YC; Gibson A; Heald N; Lamb P; Mattheakis L; Matthews D; Shipway A; Wu X; Zhang W; Zhou S; Shankar G
J Med Chem; 2012 Feb; 55(3):1368-81. PubMed ID: 22214363
[TBL] [Abstract][Full Text] [Related]
17. 2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists.
Colandrea VJ; Legiec IE; Huo P; Yan L; Hale JJ; Mills SG; Bergstrom J; Card D; Chebret G; Hajdu R; Keohane CA; Milligan JA; Rosenbach MJ; Shei GJ; Mandala SM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2905-8. PubMed ID: 16580205
[TBL] [Abstract][Full Text] [Related]
18. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.
Singh SK; Vobbalareddy S; Kalleda SR; Casturi SR; Datla SR; Mamidi RN; Mullangi R; Ramanujam R; Yeleswarapu KR; Iqbal J
Bioorg Med Chem; 2006 Dec; 14(24):8626-34. PubMed ID: 16949828
[TBL] [Abstract][Full Text] [Related]
19. Identification of benzoxazole analogs as novel, S1P(3) sparing S1P(1) agonists.
Deng G; Meng Q; Liu Q; Xu X; Xu Q; Ren F; Guo TB; Lu H; Xiang JN; Elliott JD; Lin X
Bioorg Med Chem Lett; 2012 Jun; 22(12):3973-7. PubMed ID: 22583616
[TBL] [Abstract][Full Text] [Related]
20. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
Weller T; Alig L; Beresini M; Blackburn B; Bunting S; Hadváry P; Müller MH; Knopp D; Levet-Trafit B; Lipari MT; Modi NB; Müller M; Refino CJ; Schmitt M; Schönholzer P; Weiss S; Steiner B
J Med Chem; 1996 Aug; 39(16):3139-47. PubMed ID: 8759635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
